Tailored Pig Models for Preclinical Efficacy and Safety Testing of Targeted Therapies
暂无分享,去创建一个
Andreas Blutke | Frank Seeliger | Daniel G Rudmann | Eckhard Wolf | Mohammad Bohlooly-Y | E. Wolf | M. Bohlooly-y | N. Klymiuk | F. Seeliger | D. Rudmann | Nikolai Klymiuk | A. Blutke
[1] K. Boycott,et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.
[2] Eric P. Hoffman,et al. Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.
[3] R. Prather,et al. Meganucleases Revolutionize the Production of Genetically Engineered Pigs for the Study of Human Diseases , 2016, Toxicologic pathology.
[4] Yifan Dai,et al. Targeted disruption of the α1,3-galactosyltransferase gene in cloned pigs , 2002, Nature Biotechnology.
[5] Jeong-Sun Seo,et al. Targeting efficiency of a-1,3-galactosyl transferase gene in pig fetal fibroblast cells , 2003, Experimental & Molecular Medicine.
[6] S. Richter,et al. The ΔF508 Mutation Causes CFTR Misprocessing and Cystic Fibrosis–Like Disease in Pigs , 2011, Science Translational Medicine.
[7] B. Davidson,et al. A NOVEL GENE DELIVERY METHOD TRANSDUCES PORCINE PANCREATIC DUCT EPITHELIAL CELLS , 2013, Gene Therapy.
[8] L. Touqui,et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[9] H. Kim,et al. A guide to genome engineering with programmable nucleases , 2014, Nature Reviews Genetics.
[10] Martin J. Aryee,et al. GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.
[11] Daniel F. Voytas,et al. Efficient TALEN-mediated gene knockout in livestock , 2012, Proceedings of the National Academy of Sciences.
[12] David K. Meyerholz,et al. Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn Pigs , 2008, Science.
[13] Wei Li,et al. One-step generation of knockout pigs by zygote injection of CRISPR/Cas system , 2014, Cell Research.
[14] Hong Wang,et al. Functional disruption of the dystrophin gene in rhesus monkey using CRISPR/Cas9. , 2015, Human molecular genetics.
[15] D. Sen,et al. Adeno‐associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them , 2013, Reviews in medical virology.
[16] G. Comi,et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy , 2014, Muscle & nerve.
[17] Bronwen L. Aken,et al. Analyses of pig genomes provide insight into porcine demography and evolution , 2012, Nature.
[18] S. Richter,et al. Cystic Fibrosis Pigs Develop Lung Disease and Exhibit Defective Bacterial Eradication at Birth , 2010, Science Translational Medicine.
[19] Kevin A. Rocco,et al. Efficient intratracheal delivery of airway epithelial cells in mice and pigs. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[20] Steve D. M. Brown,et al. The mammalian gene function resource: the international knockout mouse consortium , 2012, Mammalian Genome.
[21] W. Berdon,et al. Gastrointestinal manifestations of cystic fibrosis. , 1987, Seminars in roentgenology.
[22] Mark A. Kay,et al. Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.
[23] R. Prather,et al. Gene targeting with zinc finger nucleases to produce cloned eGFP knockout pigs , 2011, Molecular reproduction and development.
[24] D. Geddes,et al. Inflammation in cystic fibrosis--when and why? Friend or foe? , 2007, Seminars in Respiratory and Critical Care Medicine.
[25] A. Nakamura,et al. Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications , 2011, Journal of Biomedicine and Biotechnology.
[26] E. Wolf,et al. Sequential targeting of CFTR by BAC vectors generates a novel pig model of cystic fibrosis , 2012, Journal of Molecular Medicine.
[27] M. Nishihara,et al. Generation of muscular dystrophy model rats with a CRISPR/Cas system , 2014, Scientific Reports.
[28] George P Patrinos,et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene , 2013, Nature Genetics.
[29] R. Wanke,et al. Tissue Sampling Guides for Porcine Biomedical Models , 2016, Toxicologic pathology.
[30] Kenji Nakamura,et al. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. , 1997, Biochemical and biophysical research communications.
[31] M. Welsh,et al. Loss of Anion Transport without Increased Sodium Absorption Characterizes Newborn Porcine Cystic Fibrosis Airway Epithelia , 2010, Cell.
[32] M. Welsh,et al. Reduced Airway Surface pH Impairs Bacterial Killing in the Porcine Cystic Fibrosis Lung , 2012, Nature.
[33] M. Welsh,et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. , 2008, The Journal of clinical investigation.
[34] C. Sheridan,et al. Gene therapy finds its niche , 2011, Nature Biotechnology.
[35] J. Vogel,et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III , 2011, Nature.
[36] G. McLennan,et al. Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children. , 2010, American journal of respiratory and critical care medicine.
[37] D. Meyerholz,et al. Sonographic evidence of abnormal tracheal cartilage ring structure in cystic fibrosis , 2015, The Laryngoscope.
[38] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[39] J. Renaud,et al. Characterization of Dystrophin Deficient Rats: A New Model for Duchenne Muscular Dystrophy , 2014, PloS one.
[40] Marie-Pierre Dubé,et al. Human monogenic disorders — a source of novel drug targets , 2006, Nature Reviews Genetics.
[41] Chady H Hakim,et al. Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy , 2015, Disease Models & Mechanisms.
[42] David J. Chen,et al. DNA double strand break repair via non-homologous end-joining. , 2013, Translational cancer research.
[43] A. Muotri,et al. Pig models of neurodegenerative disorders: Utilization in cell replacement‐based preclinical safety and efficacy studies , 2014, The Journal of comparative neurology.
[44] Steve Cunningham,et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .
[45] E. Wolf,et al. Transgenic pigs as models for translational biomedical research , 2010, Journal of Molecular Medicine.
[46] Ronald G. Crystal,et al. Genetic medicines: treatment strategies for hereditary disorders , 2006, Nature Reviews Genetics.
[47] R. Finkel. Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124) , 2010, Journal of child neurology.
[48] F. Gleason,et al. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .
[49] K. Chu,et al. Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats , 2014, PloS one.
[50] E. Hoffman,et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis , 2014, Science.
[51] R. Wanke,et al. Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle. , 2013, Human molecular genetics.
[52] E. Hoffman,et al. Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. , 2013, The Journal of clinical investigation.
[53] C. Spurney. Cardiomyopathy of duchenne muscular dystrophy: Current understanding and future directions , 2011, Muscle & nerve.
[54] Jacqueline Corrigan-Curay,et al. Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[55] Michelle H. Prickett,et al. Gene therapy in cystic fibrosis. , 2013, Translational research : the journal of laboratory and clinical medicine.
[56] Florian Schmidt,et al. CRISPR genome engineering and viral gene delivery: A case of mutual attraction , 2015, Biotechnology journal.
[57] S. Matalon,et al. The CFTR and ENaC debate: how important is ENaC in CF lung disease? , 2012, American journal of physiology. Lung cellular and molecular physiology.
[58] F. Mingozzi,et al. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. , 2013, Discovery medicine.
[59] R. Wanke,et al. First inducible transgene expression in porcine large animal models , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[60] E. Wolf,et al. Genetically engineered pig models for diabetes research , 2013, Transgenic Research.
[61] INFRAFRONTIER Consortium. INFRAFRONTIER – – providing mutant mouse resources as research tools for the international scientific community , 2015 .
[62] K. Davies,et al. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.
[63] Yolanda Santiago,et al. Efficient generation of a biallelic knockout in pigs using zinc-finger nucleases , 2011, Proceedings of the National Academy of Sciences.
[64] K. Davies,et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers , 2015, Nature Medicine.
[65] Garry R. Cutting,et al. Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.
[66] David V Schaffer,et al. The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[67] K. Davies. The era of genomic medicine. , 2013, Clinical medicine.
[68] Yifan Dai,et al. Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs. , 2002, Nature biotechnology.
[69] A. Coates,et al. Efficient Gene Delivery to Pig Airway Epithelia and Submucosal Glands Using Helper-Dependent Adenoviral Vectors , 2013, Molecular therapy. Nucleic acids.
[70] David K Meyerholz,et al. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. , 2010, The Journal of clinical investigation.
[71] J. Olsen,et al. Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy. , 2014, Human gene therapy. Clinical development.
[72] Kwang-Wook Park,et al. Production of α-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning , 2002, Science.
[73] R. Finkel,et al. Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy , 2013, PloS one.
[74] Hans Clevers,et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.
[75] D. Meyerholz,et al. Sinus Hypoplasia Precedes Sinus Infection in a Porcine Model of Cystic Fibrosis , 2012, The Laryngoscope.
[76] M. Welsh,et al. Human cystic fibrosis airway epithelia have reduced Cl− conductance but not increased Na+ conductance , 2011, Proceedings of the National Academy of Sciences.
[77] T. Partridge. The mdx mouse model as a surrogate for Duchenne muscular dystrophy , 2013, The FEBS journal.
[78] Roger M. Stein,et al. Financing drug discovery for orphan diseases. , 2014, Drug discovery today.
[79] Jeffry D. Sander,et al. CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.
[80] A. Schnieke,et al. The new pig on the block: modelling cancer in pigs , 2013, Transgenic Research.
[81] E. Alton,et al. Cystic fibrosis gene therapy: successes, failures and hopes for the future , 2009, Expert review of respiratory medicine.
[82] Daniel G. Anderson,et al. Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.
[83] William H. Majoros,et al. Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy , 2015, Nature Communications.
[84] B. N. Day,et al. Production of α-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning , 2002, Science.